Trial reportCritical care (London, England)2022
Randomized controlled trial: neostigmine for intra-abdominal hypertension in acute pancreatitis.
Trial report in Critical care (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02543658 (The Curative Effect and Security of Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Curative Effect and Security of Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- AEG-AESPANC-OPGE-SIED-SPG Ibero-Latin American Guidelines on Acute Pancreatitis (iLATAM-AP).United European gastroenterology journal · 2026Guideline
- Neostigmine for non-mild acute pancreatitis: A systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2023Pooled it
- miR-1-3p, as a novel diagnostic and prognostic biomarker, aggravates pancreatic acinar cell injury in acute pancreatitis by targeting GNPTAB.Hereditas · 2026Article
- Breaking the Calcium Overload Cycle in Acute Pancreatitis: Emerging Pharmacological Strategies.Digestive diseases and sciences · 2026Review
- Cumulative intra-abdominal pressure exposure and dynamic trajectories in ICU-admitted patients reveal prognostic determinants of severe acute pancreatitis.World journal of emergency surgery : WJES · 2025Article
- Efficacy of DaXianXiong Decoction in Preventing the Progression of Acute Pancreatitis Severity: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2025Article
- Understanding the treatment of acute pancreatitis and its complications -a database for assessing traditional Chinese medicine use.Frontiers in pharmacology · 2025Article
- Feeding Intolerance-A Key Factor in the Management of Acute Pancreatitis: A Review.Journal of clinical medicine · 2024Review
- A new in-hospital mortality prediction nomogram for intensive care unit patients with acute pancreatitis.Archives of medical science : AMS · 2024Article
- Clinical characteristics and short-term outcomes of acute pancreatitis among patients with COVID-19.European journal of medical research · 2023Observational
- Intra-abdominal hypertension and abdominal compartment syndrome in acute pancreatitis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Review
- Modified Chevrel technique for abdominal closure in critically ill patients with abdominal hypertension and limited options for closure.Hernia : the journal of hernias and abdominal wall surgery · 2023Article
- Neostigmine for the treatment of acute pancreatitis: a protocol for a systematic review and meta-analysis.BMJ open · 2023Article
- Article
- Abdominal Compartment Syndrome in Acute Pancreatitis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2022Review
- Intra-Abdominal Hypertension: A Systemic Complication of Severe Acute Pancreatitis.Medicina (Kaunas, Lithuania) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundIntra-abdominal hypertension (IAH) in acute pancreatitis (AP) is associated with deterioration in organ function. This trial aimed to assess the efficacy of neostigmine for IAH in patients with AP.
methodsIn this single-center, randomized trial, consenting patients with IAH within 2 weeks of AP onset received conventional treatment for 24 h. Patients with sustained intra-abdominal pressure (IAP) ≥ 12 mmHg were randomized to receive intramuscular neostigmine (1 mg every 12 h increased to every 8 h or every 6 h, depending on response) or continue conventional treatment for 7 days. The primary outcome was the percent change of IAP at 24 h after randomization.
resultsA total of 80 patients were recruited to neostigmine (n = 40) or conventional treatment (n = 40). There was no significant difference in baseline parameters. The rate of decrease in IAP was significantly faster in the neostigmine group compared to the conventional group by 24 h (median with 25th-75th percentile: -18.7% [- 28.4 to - 4.7%] vs. - 5.4% [- 18.0% to 0], P = 0.017). This effect was more pronounced in patients with baseline IAP ≥ 15 mmHg (P = 0.018). Per-protocol analysis confirmed these results (P = 0.03). Stool volume was consistently higher in the neostigmine group during the 7-day observational period (all P < 0.05). Other secondary outcomes were not significantly different between neostigmine and conventional treatment groups.
conclusionNeostigmine reduced IAP and promoted defecation in patients with AP and IAH. These results warrant a larger, placebo-controlled, double-blind phase III trial. Trial registration Clinical Trial No: NCT02543658 (registered August /27, 2015).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.